“We have started three drug trials, namely ACQH, Favipiravir and MW. The MW trial has started very well in three different places. We are bringing about seven more into our basket of drug trials, some of which will also be combination therapies. These therapies will also come to the experimental combination of two types of medication, possibly one targeted to the virus and the other targeted to the host, ”Dr. Man to ANI.
“Of the 10 trials, seven trials are underway, and in three trials we are awaiting approval from India’s Drug Controller General (DCGI). DCGI will examine our papers and they will of course give approvals. We expect approval of the remaining seven trials for another 10 to 15 days, ”he added.
Dr. Men stated that CSIR is also working on four Ayush wording, which is a collaboration between Ayush Ministry and CSIR.
“These four formulations are ashwagandha, yashtimadhu, Gudruchi Pipli and Ayush-64. These four formulations have already entered the clinical trial registry. We have already identified the hospital. So the trial should start in a day or two,” he said.
“Several hospitals in India are trying convulsive plasma therapy. In this therapy, the plasma is taken from the person recovering from the infection and then given to the person affected by COVID-19 with the hope that antibody generated in a recovered person will help the affected person to fight the virus, ”he said.
“The IICB, Kolkata, got DCGI approval to start convalescent plasma treatment. They have bonded with a few Kolkata hospitals and have started trials now,” I added. (ANI)